Imatinib is a 2-phenylaminopyrimidine derivative neoplastic agent that has been approved by the FDA for the treatment of CML by inhibiting BCR–ABL tyrosine kinase [36]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.